ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting
ProKidney to Participate in the Guggenheim Inaugural Healthcare Innovation Conference and the Jefferies London Healthcare Conference
We're Not Very Worried About ProKidney's (NASDAQ:PROK) Cash Burn Rate [Yahoo! Finance]
ProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2024
ProKidney to Participate in the UBS Virtual Organ Restoration Day